Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Checked against the public recordLast updated Jul 22, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Amgen
- Interventions being studied
- Drug: AMG 510; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Men or women greater than or equal to 18 years old. * ECOG ≤ 1 * Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment Exclusion Criteria: * Active brain metastases * Myocardial infarction within 6 months of study day 1 * Gastrointestinal (GI) tract disease causing the inability to take oral medication
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pacific Cancer Medical Center IncAnaheim, California
- City of Hope National Medical CenterDuarte, California
- Pacific Shores Medical Group Long BeachLong Beach, California
- University of California Los AngelesLos Angeles, California
- University of California Los AngelesLos Angeles, California
- University of California at Davis Medical CenterSacramento, California
- Ridley Tree Cancer CenterSanta Barbara, California
- University of California San Francisco Mission HallStanford, California
- Harbor University of California Los Angeles Medical CenterTorrance, California
- Rocky Mountain Cancer CentersDenver, Colorado
- Danbury HospitalNorwalk, Connecticut
- Medical Oncology Hematology Consultants Helen F Graham Cancer CenterNewark, Delaware
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 22, 2026. Always confirm current availability with the study team.